Is GLP-1 a permanent medication, or can you stop?

You can stop, but the evidence says weight tends to return without a plan in place. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide, and most metabolic improvements reversed alongside it. Stopping is realistic — stopping without having built eating and training habits during treatment usually isn't.

How much does a GLP-1 cost in India in 2026?

It depends heavily on which one. Generic semaglutide, launched after the March 2026 patent expiry, starts around ₹1,300–₹1,800 per month. Branded Wegovy and Ozempic start near ₹5,600 per month at low doses following Novo Nordisk's price cuts. Mounjaro remains on patent and runs roughly ₹13,000–₹26,000 per month depending on dose.

Do Ozempic and Mounjaro cause muscle loss?

Some lean mass loss occurs with any significant weight loss. In trials, roughly 25–45% of the weight lost on GLP-1 medications came from lean tissue — broadly comparable to dieting or bariatric surgery. The concern for Indian users is the starting point: lower baseline muscle mass and lower protein intake mean the same percentage loss costs more.

Can I use a GLP-1 for just 3–6 months?

Some people do, as an accelerator rather than a permanent therapy. It works when the medication window is used to build portion control, protein-first eating, and strength training. Without that, a short course usually just delays regain. This decision should be made with your prescribing doctor, not independently.

Why are GLP-1 risks different for Indians?

At the same BMI, Asian Indians typically carry more visceral fat and less skeletal muscle than European-ancestry populations. Average protein intake also sits below requirements before any appetite suppression begins. Cut appetite sharply on that baseline and protein intake falls further, accelerating muscle loss.

Now that generics are cheap, can I just start on my own?

No. GLP-1 medications are Schedule H prescription drugs in India and require a valid prescription. Lower prices removed a cost barrier, not a medical one — dosing, titration, contraindications, and monitoring for side effects all still require a doctor.

Ozempic & Mounjaro: The Real Risks of GLP-1 Misuse in India

GLP-1 Isn't a Miracle. Misusing It Is the Real Risk.

Written by Rishi Bhojnagarwala

Medically Reviewed by Dr. Hetal Pal, PhD in Nutrition Science

Over the past year, GLP-1 medications like Ozempic, Wegovy, and Mounjaro have gone from clinical tools to mass-market headlines in India.

What's more interesting is who is now advertising them.

Many of the same companies that were, until recently, selling lifestyle programs, diet plans, supplements, and "sustainable weight loss" courses have suddenly changed their narrative.

Lifestyle doesn't work, they now say. Biology must be fixed. GLP-1 is the answer.

This sudden shift deserves a closer look — especially now that the price of entry has collapsed.

We spoke to Dr. Paul Gross, Primary Care Physician and Medical Doctor at LIV3 Health

(Dr. Paul Gross, a Medical Doctor at LIV3 Health with extensive experience helping patients manage obesity, metabolic health, and sustainable weight loss through evidence-based nutrition, lifestyle strategies, and medical treatment.)

1. What's the most common way you see patients misuse or mismanage GLP-1 medications in practice?

Dr Gross: The most common error that I see in my practice is when patients believe they can eliminate their healthy behaviors to lose weight with GLP-1 medications. Most commonly, this means the patient is eating too low a quantity of protein, does not have enough muscle mass through resistance training (strength training), or believes that by reducing hunger they will lose weight on their own without implementing any other long-term lifestyle changes.

2. For Indian patients specifically — higher visceral fat, lower baseline protein intake — does that change how you'd approach GLP-1 dosing or monitoring compared to Western patients?

Dr Gross: My counseling approach for many of my Indian patients differs in that I give them closer attention to their protein intake and muscle preservation and waist circumference as well. Visceral fat (fat around the abdominal area) increases metabolic risk and contributes to the development of diabetes and other conditions, even when body weight is normal or low. This should be monitored closely during the entire duration of treatment.

3. If someone wants to use GLP-1 short-term rather than indefinitely, what needs to be true for that to work without rebound weight gain?

Dr Gross: Long-term success with diet medications is based upon developing habits that will continue even after you have finished taking the medication. Before discontinuing the medication, patients should be able to maintain a routine of eating at consistent times each day, obtain adequate amounts of protein, perform some form of regular physical activity, and develop a reasonable expectation as to how they can achieve their goals. If these habit-forming components are not present, most likely when you stop taking the medication, your hunger will return and achieving long-term weight loss will become much more difficult.

What GLP-1 Actually Does (And What It Doesn't)

GLP-1 medications don't "melt fat."

They don't magically fix metabolism.

What they do — very effectively — is reduce appetite and food cravings.

That's it.

And that's powerful.

For someone who is already motivated, already trying, and already understands what weight loss requires, GLP-1 simply removes the biggest friction point: constant hunger.

In other words, GLP-1 fast-tracks something people have always attempted on their own — a calorie deficit — but struggled to sustain. If you're still working out how these drugs differ from one another, our guide to GLP-1 medicines available in India and our breakdown of Ozempic vs Mounjaro cover the basics.

The Barrier That Just Disappeared

Until recently, cost quietly rationed GLP-1 access in India. That's over.

On 20 March 2026, the Indian patent on semaglutide expired — the molecule behind both Ozempic and Wegovy. Within days, multiple Indian manufacturers launched generic versions at roughly 70% below the branded price, with some vial formats starting near ₹1,290 a month. Novo Nordisk responded by cutting Ozempic and Wegovy prices by up to 36% and 48% respectively — its second price cut in five months.

So the Indian market now looks roughly like this:

Generic semaglutide: from about ₹1,300–₹1,800 per month
Branded Wegovy / Ozempic: from about ₹5,600 per month at starting doses
Mounjaro (tirzepatide, still on patent): roughly ₹13,000–₹26,000 per month depending on dose

For context on how India got here, we covered the patent and adoption story separately.

This is genuinely good news for people who medically need these drugs. It is also precisely why the misuse conversation matters more now, not less. When a medication costs ₹16,000 a month, people think hard before starting. When it costs ₹1,300, the thinking often stops — and so does the medical supervision that should come with it.

Affordability solved the access problem. It did not solve the guidance problem.

The Inconvenient Truth No One Is Talking About

GLP-1 is not a one-time solution.

For most users, it becomes a long-term medication, a recurring monthly expense, and a dependency that must be managed carefully.

What many ads don't disclose clearly is what happens when you stop.

In the STEP 1 trial extension, participants who lost an average of 17.3% of their body weight on semaglutide were followed for a year after treatment was withdrawn. They regained roughly two-thirds of what they'd lost. Most of the cardiometabolic improvements — blood pressure, lipids, blood sugar markers — drifted back toward baseline as well.

This doesn't make GLP-1 bad. It makes how it's used extremely important.

Can GLP-1 Be Used Short-Term?

Yes — but only if used correctly.

A 3–6 month GLP-1 phase can work as a powerful accelerator, provided users simultaneously:

Learn portion control
Build protein-first eating habits
Actively preserve muscle mass
Address digestion and nutrient gaps
Create routines they can sustain after the medication ends

Without this, GLP-1 simply postpones the problem. The appetite suppression buys you a window. What you build inside that window determines whether the weight stays off.

The Muscle Question — And Why It's Bigger in India

When you lose weight rapidly, some of what you lose is muscle. This is true of dieting, bariatric surgery, and GLP-1 medications alike

The numbers are worth knowing. A 2024 review in Diabetes, Obesity and Metabolism found that in the STEP 1 trial, about 45% of the weight lost on semaglutide came from lean mass. In SURMOUNT-1, the tirzepatide trial, the figure was closer to 26%.

GLP1 muscle loss Ozempic vs mounjaro

Here's the honest counterpoint, because it matters: in several of these trials, lean mass as a proportion of total body mass actually improved, and the overall range — roughly 20–50% of weight lost — is broadly in line with what's seen in diet-induced weight loss and bariatric surgery. GLP-1 drugs are not uniquely destroying muscle. We've written more about where GLP-1 fear-mongering outruns the evidence.

But that reassurance was calculated on populations that generally start with more muscle than the average Indian does.

Why This Is Especially Critical for Indians

Indians carry a distinct metabolic profile. At any given BMI, Asian Indians tend to have higher body fat, more visceral fat, and less skeletal muscle mass than European-ancestry populations — the pattern researchers call the thin-fat phenotype.

Layer protein intake on top. The ICMR-NIN RDA is 0.83 g/kg/day — and the same guidance notes that for people eating cereal-based diets with lower-quality protein, requirements rise to about 1 g/kg/day. That describes most Indian households. Our analysis of where India's real protein gap actually sits puts the average shortfall at 15–25 grams a day before anyone starts a GLP-1.

Now suppress that person's appetite by 30–40%.

Appetite suppression without guidance often leads to:

Skipped meals
Protein intake falling well below maintenance needs
Digestive distress and constipation
Fatigue and weakness
Accelerated loss of muscle that was already limited

This is not a failure of GLP-1. It's a failure of support systems. Someone starting at low muscle mass and low protein intake, then losing a quarter to nearly half of their weight loss as lean tissue, ends up thinner and metabolically worse off. That's the outcome nobody advertises. It's also related to what people notice in the mirror — we explained what's actually happening with "Ozempic face".

Pharma Will Own Weight Loss — But Not Behavior

For most of the last century, weight loss remained a fragmented market:

Nutritionists managing a handful of clients
Gyms selling memberships
Apps selling subscriptions
Supplements promising shortcuts

Despite billions in value, obesity kept rising.

GLP-1 changes that equation. Pharma now owns the most effective lever we've ever had for appetite control.

But appetite control alone is not health.

Behaviour, nutrition, muscle preservation, and long-term adherence cannot be solved by a prescription alone. And the stigma still attached to using these medications in India pushes many people to start quietly, without telling a doctor — which is exactly the wrong way to begin.

The Right Way Forward: A Complete Metabolic Stack

If we truly want to reduce obesity — not just sell medication — the approach has to combine:

Medication (GLP-1), prescribed and monitored properly
Technology — tracking, feedback, and compliance you'll actually maintain
Nutrition intelligence — culturally accurate, protein-aware, built for how Indians actually eat
Coaching and clinical oversight
Screening for nutrient gaps during reduced intake, and correcting them under medical guidance

GLP-1 is an incredible discovery. But it works best when used thoughtfully — short-term or long-term — with the right system around it. That's the thinking behind our GLP-1 companion approach and our India-specific GLP-1 diet plan.

The real question isn't whether GLP-1 works.

It's whether we're ready to use it responsibly.

If you're considering a GLP-1 — or already on one and unsure whether your nutrition is holding up — start with an eligibility check rather than a pharmacy counter.

This article is for general information only and is not medical advice. GLP-1 medications are prescription-only in India and should be started, adjusted, or stopped only under the supervision of a qualified doctor.

About Caddy

Caddy is a weight loss and nutrition companion built for how Indians actually eat. Instead of forcing you into a food database designed for someone else's kitchen, Caddy is powered by deep, India-first nutrition data — so tracking dal, roti, poha, or last night's biryani reflects what you actually ate.

For anyone on a GLP-1, that matters more than usual. When appetite drops sharply, every meal has to work harder. Caddy helps you keep protein and fibre where they need to be, spot the days your intake quietly collapsed, and build habits that hold up after the medication stops.

Clarity beats willpower. Caddy helps you see better, so you can do better.

GLP-1 Isn’t a Miracle. Misusing It Is the Real Risk.